Results 151 to 160 of about 68,749 (310)

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

open access: yesJEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz   +2 more
wiley   +1 more source

Myasthenia Gravis and Thymoma

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor   +5 more
wiley   +1 more source

Major Histocompatibility Complex Class I Matching is Necessary but not Sufficient for Tolerance Induction to Vascularized Composite Allografts After Donor Hematopoietic Cell Transplantation. [PDF]

open access: yesTransplant Direct
Manell E   +19 more
europepmc   +1 more source

Proteome Analysis of Corynebacterium diphtheriae–Macrophage Interaction

open access: yesPROTEOMICS, EarlyView.
ABSTRACT Contact of Corynebacterium diphtheriae with macrophages induces adaptations on both bacterial and cellular sides. The study presented here was aiming to shed light on the simultaneous intracellular adaptation of the bacteria and changes in the proteome of the phagocytes in response to the internalization of C. diphtheriae.
Luca Musella   +6 more
wiley   +1 more source

Mapping the Landscape of Host-Pathogen Coevolution: HLA Class I Binding and Its Relationship with Evolutionary Conservation in Human and Viral Proteins

open access: yes, 2011
The high diversity of HLA binding preferences has been driven by the sequence diversity of short segments of relevant pathogenic proteins presented by HLA molecules to the immune system.
Jojic, N.   +9 more
core  

Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao   +4 more
wiley   +1 more source

HLA Class I Loss and Resistance to Immunotherapy in Pulmonary Metastasis of Hypopharyngeal Cancer. [PDF]

open access: yesIn Vivo
Murakami A   +6 more
europepmc   +1 more source

Integrative Modeling in the Age of Machine Learning: A Summary of HADDOCK Strategies in CAPRI Rounds 47–55

open access: yesProteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT The HADDOCK team participated in CAPRI rounds 47–55 as server, manual predictor, and scorers. Throughout these CAPRI rounds, we used a plethora of computational strategies to predict the structure of protein complexes. Of the 10 targets comprising 24 interfaces, we achieved acceptable or better models for 3 targets in the human category and 1 ...
Victor Reys   +16 more
wiley   +1 more source

Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor Activity. [PDF]

open access: yesCells
Richert I   +6 more
europepmc   +1 more source

Massive Sampling Strategy for Antibody–Antigen Targets in CAPRI Round 55 With MassiveFold

open access: yesProteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT Massive sampling with AlphaFold2 improves protein–protein complex predictions. This has been shown during the last CASP15‐CAPRI blind prediction round by the AFsample tool. However, more difficult targets including antibody–antigen binding remain challenging. CAPRI Round 55 consisted of three antibody–antigen targets and one heterotrimer.
Nessim Raouraoua   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy